b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">\n        <PMID Version="1">32214002</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>21</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Print">2075-4418</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>10</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Mar</Month>\n                        <Day>24</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Diagnostics (Basel, Switzerland)</Title>\n                <ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Predictive Analyses of Prognostic-Related Immune Genes and Immune Infiltrates for Glioblastoma.</ArticleTitle>\n            <ELocationID EIdType="pii" ValidYN="Y">E177</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics10030177</ELocationID>\n            <Abstract>\n                <AbstractText>Glioblastoma (GBM), the most common and aggressive brain tumor, has a very poor outcome and high tumor recurrence rate. The immune system has positive interactions with the central nervous system. Despite many studies investigating immune prognostic factors, there is no effective model to identify predictive biomarkers for GBM. Genomic data and clinical characteristic information of patients with GBM were evaluated by Kaplan-Meier analysis and proportional hazard modeling. Deseq2 software was used for differential expression analysis. Immune-related genes from ImmPort Shared Data and the Cistrome Project were evaluated. The model performance was determined based on the area under the receiver operating characteristic (ROC) curve. CIBERSORT was used to assess the infiltration of immune cells. The results of differential expression analyses showed a significant difference in the expression levels of 2942 genes, comprising 1338 upregulated genes and 1604 downregulated genes (<i>p</i> &lt; 0.05). A population of 24 immune-related genes that predicted GBM patient survival was identified. A risk score model established on the basis of the expressions of the 24 immune-related genes was used to evaluate a favorable outcome of GBM. Further validation using the ROC curve confirmed the model was an independent predictor of GBM (AUC = 0.869). In the GBM microenvironment, eosinophils, macrophages, activated NK cells, and follicular helper T cells were associated with prognostic risk. Our study confirmed the importance of immune-related genes and immune infiltrates in predicting GBM patient prognosis.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Liang</LastName>\n                    <ForeName>Ping</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Clinical Medicine, Tsinghua University, Beijing 100084, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chai</LastName>\n                    <ForeName>Yi</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Clinical Medicine, Tsinghua University, Beijing 100084, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>He</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Materials, Tsinghua University, Beijing 100084, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wang</LastName>\n                    <ForeName>Guihuai</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>School of Clinical Medicine, Tsinghua University, Beijing 100084, China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>24</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Switzerland</Country>\n            <MedlineTA>Diagnostics (Basel)</MedlineTA>\n            <NlmUniqueID>101658402</NlmUniqueID>\n            <ISSNLinking>2075-4418</ISSNLinking>\n        </MedlineJournalInfo>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">glioblastoma</Keyword>\n            <Keyword MajorTopicYN="N">immune-related</Keyword>\n            <Keyword MajorTopicYN="N">prediction value</Keyword>\n            <Keyword MajorTopicYN="N">prognosis</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>09</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>14</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>19</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>1</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32214002</ArticleId>\n            <ArticleId IdType="pii">diagnostics10030177</ArticleId>\n            <ArticleId IdType="doi">10.3390/diagnostics10030177</ArticleId>\n            <ArticleId IdType="pmc">PMC7151008</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Nat Rev Clin Oncol. 2018 Jul;15(7):422-442</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29643471</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Tumour Biol. 2014 Nov;35(11):11091-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25099618</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Glia. 2002 Nov;40(2):252-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12379912</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Neuron. 2019 Nov 6;104(3):442-449</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">31697921</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2014 Oct 15;20(20):5290-301</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24691018</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2019 Jul 15;25(14):4202-4210</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">30804019</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2013 Jul 15;19(14):3776-86</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23741072</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2017 Mar 16;376(11):1027-1037</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28296618</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Rev Immunol. 2013 Jul;13(7):499-509</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23787991</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2015 Jun 25;372(26):2481-98</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26061751</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Cancer Inst. 2011 Apr 6;103(7):598-606</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21346226</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Neuro Oncol. 2008 Feb;10(1):98-103</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18079360</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 1989 May 5;57(3):503-12</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">2785856</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Neuropathol Exp Neurol. 2005 Jun;64(6):523-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15977644</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Cell. 2018 Jan 8;33(1):152</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29316430</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 2014 Apr 24;157(3):580-94</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24726434</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Neurosci. 2016 Jun;19(6):798-806</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27110918</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Immunol. 2002 May 1;168(9):4772-80</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11971028</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):31-42</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11418300</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Commun. 2013;4:2612</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24113773</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Genome Biol. 2016 Nov 17;17(1):231</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27855702</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Acta Neuropathol. 2016 Jun;131(6):803-20</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27157931</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2005 Mar 10;352(10):987-96</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15758009</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Exp Immunol. 2012 Nov;170(2):186-93</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23039889</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'